Transcriptome Analysis of Gene Expression involving C/EBPβ and Olaparib Resistance

Poly(ADP-ribose) polymerase inhibitors (PARPi) are now widely used in treating ovarian cancer. However, PARPi resistance emerges gradually. To investigate the change of gene expression during the transition, we have induced a stable resistant cell strain by culturing A2780 in the continued presence of olaparib. We then performed RNA-seq of the resistant strain and its parent line A2780. We found that C/EBPβ was strongly correlated with PARPi resistance. RNA-seq of C13* after C/EBPβ knockdown was also performed. Examination of differentially expressed genes in A2780 Olaparib-resistant cell line and its parent line A2780 and in C13* cells after C/EBPβ knockdown